Neuralink的“闪光”视觉恢复植入 得到了FDA的“突破装置”的称谓 Neuralink's "Blindsight" vision restoration implant receives FDA's "breakthrough device" designation.

埃隆·马斯克创办的神经技术初创公司Neuralink因其视力恢复植入物"盲视"而获得美国FDA的"突破性设备"认证. Neuralink, Elon Musk's neurotechnology startup, has received "breakthrough device" designation from the U.S. FDA for its vision restoration implant, "Blindsight." 这一指定加快了治疗危及生命状况的装置的研制。 This designation expedites the development of devices treating life-threatening conditions. 植入物旨在帮助盲人绕过受损的光学通道。 The implant aims to assist those who are blind, bypassing damaged optic pathways. Neuralink也在测试技术, 让瘫痪的病人能够用思想控制数字设备, 试验预计会持续数年。 Neuralink is also testing technology that allows paralyzed patients to control digital devices with their thoughts, with trials expected to last several years.